Moreover, in normal cells, PPARα antagonist did not inhibit the glycolysis; conversely, in RCC, cell line glycolysis was attenuated, which was likely due to a difference of c-Myc protein levels between cancer cells and normal cells [105]. This evidence concerns the gene MYC and renal cell carcinoma.